Testosterone Label Changes 2026: What FDA Did and Didn't Do

Testosterone label changes 2026 are easy to confuse with changes made in 2025. On February 28, 2025, FDA told makers of all testosterone products to add TRAVERSE trial results and remove cardiovascular-outcomes language from the Boxed Warning. In June 2026, FDA requested more updates: dropping the age-related limitation of use and revising prostate cancer and enlarged-prostate safety information. Those are requests. None of it makes anyone automatically eligible for treatment.

Key takeaways

• On February 28, 2025, FDA told sponsors of all testosterone products to add TRAVERSE results, remove cardiovascular-outcomes language from the Boxed Warning, keep the age-related limitation of use and add blood pressure warnings (FDA, 2025).
• In June 2026, FDA requested updates that would remove the age-related limitation of use and revise prostate cancer and BPH (benign prostatic hyperplasia, an enlarged prostate) safety information (FDA Testosterone Information, 2026).
• None of these steps makes anyone automatically eligible, because diagnosis still requires symptoms plus consistently low morning testosterone confirmed by repeat testing (Endocrine Society, 2018).
• This article covers what drug labels say, while our guide to the DEA telemedicine rule and testosterone covers how testosterone can be prescribed through telehealth.

Testosterone label changes 2026: the timeline at a glance

Two separate actions get blurred together: the February 2025 class-wide changes and the June 2026 requested updates. The 2025 action was a set of labeling changes FDA told sponsors to make; the June 2026 step is a request for further updates.

A Boxed Warning is the most prominent warning in a drug's prescribing information, printed in a box at the top. Prescribing information is the official FDA-approved label for a specific product.

A quick way to date a claim: Boxed Warning changes and new blood pressure warnings come from 2025, while removing the age-related limitation of use and revising prostate and BPH information come from the June 2026 request.

What the FDA changed in 2025, and what it kept

In February 2025, FDA told sponsors to add TRAVERSE results to all testosterone labeling and to remove Boxed Warning language about increased risk of adverse cardiovascular outcomes. It kept the age-related limitation of use and added blood pressure warnings (FDA, 2025).

• Changed: TRAVERSE results added to all products, and cardiovascular-outcomes language removed from the Boxed Warning.
• Kept: the limitation of use for age-related hypogonadism. The June 2026 request would remove it, so check the date on any claim about it.
• Added: blood pressure information. Completed ambulatory blood pressure monitoring (ABPM) studies, which track blood pressure with a cuff worn through the day and night, confirmed increases with all testosterone products. FDA required product-specific information on increased blood pressure, plus a new blood pressure warning for products that lacked one (FDA, 2025).

TRAVERSE was a randomized, double-blind, placebo-controlled noninferiority trial, meaning it was designed to test whether testosterone was not meaningfully worse than placebo on heart outcomes. It enrolled 5,246 men aged 45 to 80 with hypogonadism (low testosterone with symptoms) and preexisting cardiovascular disease or high cardiovascular risk (NEJM, 2023). Major adverse cardiovascular events occurred in 7.0% of men on testosterone gel and 7.3% on placebo, and FDA found no new safety signal (FDA Testosterone Information, 2026).

The limits matter. TRAVERSE tested a topical gel, AndroGel 1.62% (FDA Testosterone Information, 2026), in men with confirmed hypogonadism, so its results do not directly describe injectable testosterone. For the full trial breakdown, see what the TRAVERSE trial actually showed.

What FDA requested in June 2026

In June 2026, FDA requested three updates to testosterone prescribing information: remove the age-related hypogonadism limitation of use, revise prostate cancer safety information and revise BPH safety information (FDA Testosterone Information, 2026). These are requested updates, not confirmed changes to every product's label.

Status is the part to watch. A request asks sponsors to update their labeling. We have not verified whether each sponsor has done so as of this writing. If you take or are considering a specific product, check its current prescribing information and ask your clinician.

What removing the age-related limitation of use means, and what it doesn't

Removing a limitation of use deletes a caveat. It does not add a new approved use, and FDA's own page still says testosterone products are approved only for men with low testosterone "in conjunction with an associated medical condition" (FDA Testosterone Information, 2026).

Two terms help here:

• An indication is the use FDA approved a drug for.
• A limitation of use is a caveat in the Indications section saying safety or effectiveness has not been established in a particular group.

FDA lists examples of associated conditions, such as testicular failure from genetic problems or chemotherapy, and hypothalamic or pituitary problems. Its page states that none of the FDA-approved testosterone products are approved for men with low testosterone who lack an associated condition (FDA Testosterone Information, 2026).

One more definition clarifies the request. FDA's page defines age-related hypogonadism as signs and symptoms of low testosterone without a clear cause (FDA Testosterone Information, 2026). That group is different from men with low testosterone and an associated medical condition, which is the group the approved indication covers.

What the June 2026 request says about prostate cancer and BPH

FDA's June 2026 request asks sponsors to revise prostate cancer and BPH safety information (FDA Testosterone Information, 2026). The specific wording depends on each product's updated label, so check current prescribing information.

The main evidence is the TRAVERSE prostate safety analysis, a prespecified part of the randomized trial (JAMA Netw Open, 2023):

• 5,204 men aged 45 to 80, with 14,304 person-years of follow-up.
• High-grade prostate cancer: 5 of 2,596 (0.19%) on testosterone gel and 3 of 2,602 (0.12%) on placebo. The difference was not statistically significant, and the wide confidence interval shows real uncertainty.
• PSA (prostate-specific antigen, a blood marker) rose more in the testosterone group.
• Change in IPSS (International Prostate Symptom Score, a urinary symptom questionnaire) did not differ between groups.

Who was excluded matters as much as the result. The trial left out men with a history of prostate or breast cancer, PSA above 3.0 ng/mL, severe lower urinary tract symptoms or a prostate nodule. The authors said the findings should not be applied to men with known prostate cancer, higher PSA or unconfirmed hypogonadism, and noted that carcinogens may take many years to cause cancer (JAMA Netw Open, 2023).

On BPH (benign prostatic hyperplasia, an enlarged prostate), FDA's June 2026 request asks sponsors to revise safety information (FDA Testosterone Information, 2026). In TRAVERSE, change in IPSS did not differ between groups, but men with severe urinary symptoms were excluded (JAMA Netw Open, 2023). For more, read the evidence on TRT and prostate cancer.

Does a label change mean more men qualify for TRT?

Not automatically. Label text tells clinicians about evidence and risk. It does not diagnose anyone or set an approval threshold.

The diagnostic standard has not moved. The Endocrine Society recommends diagnosing hypogonadism only when symptoms and signs of testosterone deficiency come with unequivocally and consistently low testosterone. It recommends a fasting morning total testosterone test as the first step, confirmed by repeating it (Endocrine Society, 2018).

For older men, the guideline suggests against routinely prescribing testosterone to everyone 65 or older with low levels. It favors individualized decisions after a discussion of risks and benefits in men with symptoms and consistently low levels (Endocrine Society, 2018).

If sponsors update their labels as requested, the age-related caveat would no longer appear, but that does not confirm anyone's diagnosis. What stays: someone has to confirm the diagnosis, screen and monitor. Not everyone qualifies, and that's how it should work.

Why labs and monitoring still matter

The current evidence still supports careful evaluation. Four reasons:

1. Diagnosis depends on repeat morning lab testing, not a single number or a symptom quiz (Endocrine Society, 2018).
2. In TRAVERSE, PSA rose more in men on testosterone, which is one reason prostate monitoring stays part of care (JAMA Netw Open, 2023).
3. The 2025 changes added class-wide blood pressure warnings based on ABPM studies (FDA, 2025). That is a reason for ongoing check-ins.
4. TRAVERSE's findings apply to men like those enrolled: confirmed hypogonadism, carefully screened, using a topical gel (NEJM, 2023; JAMA Netw Open, 2023).

Fertility goals are also part of the conversation, since testosterone therapy can affect sperm production. For which tests are typically involved, see TRT blood work before and during therapy.

How access works through New Blue

New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.

Every testosterone pathway on New Blue is synchronous, meaning it includes a live clinician visit plus lab work. That live visit is part of the pathway's own process, not something the label changes require:

1. You complete a health intake and schedule a live visit with a licensed clinician.
2. Lab work is part of the evaluation.
3. Based on your visit, labs and clinical review, a licensed clinician decides whether treatment is appropriate.
4. If prescribed, a licensed partner pharmacy ships the medication directly to you, with your clinician's guidance and pharmacy instructions.

This is for adults 21 and older and is not for emergencies. Consultation timing varies by clinician availability. If treatment isn't appropriate, refunds follow our refund policy. Availability varies by state, so check state availability. For current pricing and details, see the injectable testosterone protocol.

Frequently Asked Questions

Did the FDA remove the testosterone boxed warning?

In February 2025, FDA told sponsors to remove Boxed Warning language about increased risk of adverse cardiovascular outcomes. That followed the TRAVERSE trial, which found no increase in major cardiovascular events with testosterone gel compared with placebo. Describing this as removing the entire Boxed Warning overstates what FDA announced.

Is testosterone now FDA-approved for age-related low testosterone?

No new indication for age-related low testosterone has been announced. In June 2026, FDA requested removal of a limitation of use, which is a caveat, not an approval. FDA's Testosterone Information page still says approved products are for low testosterone with an associated medical condition.

Did TRAVERSE test injectable testosterone?

No. TRAVERSE used a topical gel, AndroGel 1.62%, so its results do not directly describe injections (FDA Testosterone Information, 2026). A clinician weighs that when discussing options.

Can men with prostate cancer use testosterone therapy under the new labels?

Current evidence does not settle this question, and FDA's June 2026 request to revise prostate cancer safety information is a requested update, not a confirmed label change. The TRAVERSE prostate analysis excluded men with prostate cancer history or higher PSA, so its findings do not apply to them. Any decision belongs to a licensed clinician, often alongside a urologist.

Do I still need blood work for testosterone therapy?

Yes. The Endocrine Society recommends diagnosing low testosterone only with symptoms plus consistently low morning levels confirmed by repeat testing. The 2025 labeling changes also added blood pressure warnings for all testosterone products, which is one reason monitoring continues.

Do the label changes affect how telehealth testosterone works?

No. FDA labeling and DEA rules on prescribing controlled substances through telehealth are separate tracks. A label update changes the prescribing information clinicians read, not the rules for how a visit must happen.

Sources

1. FDA issues class-wide labeling changes for testosterone products. U.S. Food and Drug Administration, 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products
2. Testosterone Information. U.S. Food and Drug Administration, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/testosterone-information
3. Cardiovascular Safety of Testosterone-Replacement Therapy. The New England Journal of Medicine, 2023. https://pubmed.ncbi.nlm.nih.gov/37326322/
4. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Network Open, 2023. https://pubmed.ncbi.nlm.nih.gov/38150256/
5. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism, 2018. https://pubmed.ncbi.nlm.nih.gov/29562364/

Medical disclaimer: This article is for educational purposes only and is not medical advice. Treatment decisions are made by a licensed clinician based on your history, examination and lab results. New Blue Health is a technology and administrative services platform, not a medical provider.